Ignite Creation Date:
2025-12-24 @ 10:00 PM
Ignite Modification Date:
2025-12-25 @ 7:37 PM
Study NCT ID:
NCT04700332
Status:
RECRUITING
Last Update Posted:
2021-07-27
First Post:
2021-01-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2023-03-27', 'mcpReleaseN': 4, 'releaseDate': '2023-03-01'}, {'resetDate': '2023-06-26', 'mcpReleaseN': 5, 'releaseDate': '2023-06-02'}, {'resetDate': '2024-10-21', 'mcpReleaseN': 6, 'releaseDate': '2024-09-30'}, {'resetDate': '2025-12-02', 'mcpReleaseN': 7, 'releaseDate': '2025-12-02'}], 'estimatedResultsFirstSubmitDate': '2023-03-01'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 184}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2021-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-07', 'completionDateStruct': {'date': '2022-12-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-07-26', 'studyFirstSubmitDate': '2021-01-04', 'studyFirstSubmitQcDate': '2021-01-06', 'lastUpdatePostDateStruct': {'date': '2021-07-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-01-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-07-15', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Detection of unsuspected metastases in high risk prostate cancer', 'timeFrame': 'up to 4 weeks', 'description': 'Determine the rate of detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or radiation therapy.'}, {'measure': 'Detection of unsuspected metastases in biochemically recurrent prostate cancer', 'timeFrame': 'up to 4 weeks', 'description': 'Determine the rate of detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, yet no evidence of disease on CT/bone scan.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Prostate Cancer', 'DCFPyL PET/CT', 'Staging', 'Biochemical relapse'], 'conditions': ['Prostate Cancer']}, 'referencesModule': {'references': [{'pmid': '35852431', 'type': 'DERIVED', 'citation': 'Ulaner GA, Thomsen B, Bassett J, Torrey R, Cox C, Lin K, Patel T, Techasith T, Mauguen A, Rowe SP, Lindenberg L, Mena E, Choyke P, Yoshida J. 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation. Radiology. 2022 Nov;305(2):419-428. doi: 10.1148/radiol.220218. Epub 2022 Jul 19.'}]}, 'descriptionModule': {'briefSummary': 'The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.', 'detailedDescription': 'This will be a phase II clinical trial to assess the clinical value of PyL for detection of disease in pateints with:\n\n1. High risk prostate cancer and planned prostatectomy or radiation therapy (arm 1) and\n2. Biochemically recurrent prostate cancer (arm 2) but without evidence of disease of standard of care imaging (CT of the chest/abdomen/pelvis and bone scan).\n\nIn both cohorts, PyL PET/CT will be obtained and evaluated by a nuclear radiologist trained in novel PET radiotracers, including PyL. Lesions suspicious for disease of PyL that were unsuspected on standard of care imaging will be selected for biopsy for pathologic confirmation if feasible . Pathology will be used as the reference standard for confirming malignancy.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Male ≥ 18 years of age.\n2. Histologically confirmed adenocarcinoma of the prostate\n3. Patients meet one of the follow criteria:\n\nCohort 1: High risk prostate cancer (PSA \\>10, Gleason 8-10, or clinical stage \\>T2c) and planned prostatectomy or radiation therapy or Cohort 2: Biochemical prostate cancer relapse (Prostate Specific Antigen (PSA) \\> 0.2 ng/ml in patients following prostatectomy or ≥ 2 ng/ml more than the PSA nadir in patient following radiotherapy, as defined by the ASTRO-Phoenix criteria \\[18\\] and no evidence of malignancy on standard of care imaging for metastases (CT of the chest/abdomen/pelvis and bone scan) within 3 months.\n\nExclusion Criteria:\n\n1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n2. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.\n3. Change in therapy since standard of care imaging'}, 'identificationModule': {'nctId': 'NCT04700332', 'briefTitle': 'PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Hoag Memorial Hospital Presbyterian'}, 'officialTitle': '2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer', 'orgStudyIdInfo': {'id': '184-20-CA'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'High risk prostate cancer', 'description': 'DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy', 'interventionNames': ['Drug: DCFPyL PET/CT']}, {'type': 'EXPERIMENTAL', 'label': 'Biochemically recurrent prostate cancer', 'description': 'DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.', 'interventionNames': ['Drug: DCFPyL PET/CT']}], 'interventions': [{'name': 'DCFPyL PET/CT', 'type': 'DRUG', 'description': 'Prostate Membrane Specific Antigen-specific imaging', 'armGroupLabels': ['Biochemically recurrent prostate cancer', 'High risk prostate cancer']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92618', 'city': 'Irvine', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Beth Thomsen', 'role': 'CONTACT', 'email': 'beth.thomsen@hoag.org'}, {'name': 'Gary Ulaner, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hoag Memorial Hospital Presbyterian', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}], 'centralContacts': [{'name': 'Beth Thomsen', 'role': 'CONTACT', 'email': 'clinicalresearch@hoag.org', 'phone': '949-764-4577'}], 'overallOfficials': [{'name': 'Deborah Fridman, PsyD, RN', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoag Memorial Hospital Presbyterian'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoag Memorial Hospital Presbyterian', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director Molecular Imaging and Therapy', 'investigatorFullName': 'Gary Ulaner', 'investigatorAffiliation': 'Hoag Memorial Hospital Presbyterian'}}}}